Drug Trial Radar · NCT00932451
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Last checked: Nov 19, 2026Latest source record: Jan 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,069
Actual
Start
Jan 2010
Primary completion
Mar 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066Drug
PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: 6 years
- Percentage of Participants With Adverse EventsTime frame: 6 years
Locations
280 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Comprehensive Blood and Cancer Center
Bakersfield, California
Tower Cancer Research Foundation
Beverly Hills, California
Tower Hematology Oncology Medical Group
Beverly Hills, California
Moores UCSD Cancer Center
La Jolla, California
UCSD Medical Center - La Jolla
La Jolla, California
Drug Shipping Address: Ronald Reagen University of California-Los Angeles
Los Angeles, California
Ronald Reagen University of California-Los Angeles Medical Center
Los Angeles, California
UCLA Opthalmic Oncology Center
Los Angeles, California
University of California-Los Angeles
Los Angeles, California
University of California, Irvine-Medical Center
Orange, California
University of California, Irvine-Pharmacy
Orange, California
Stanford University-Cancer Center
Palo Alto, California
UC Davis Cancer Center
Sacramento, California
University of California Davis Medical Center
Sacramento, California
UCSD Medical Center - Hillcrest
San Diego, California
Santa Monica-UCLA Medical Center & Orthopaedic Hospital Clinical Laboratory
Santa Monica, California
UCLA Hematology Oncology-Santa Monica
Santa Monica, California
University of California-Los Angeles
Santa Monica, California
Redwood Regional Medical Group Inc
Santa Rosa, California
DRUG SHIPMENT: University of Colorado Cancer Center
Aurora, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
Kaiser Permanente Colorado - Franklin
Denver, Colorado
Kaiser Permanente Colorado - Rock Creek
Lafayette, Colorado
Smilow Cancer Center at Yale New Haven, Oncology Pharmacy
New Haven, Connecticut
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Yale University
New Haven, Connecticut
Michael and Dianne Bienes Cancer Center, Holy Cross Hospital
Fort Lauderdale, Florida
Memorial Cancer Institute
Hollywood, Florida
Cancer Center of South Florida Foundation, Inc.
Lake Worth, Florida
Memorial Cancer Center (West)
Pembroke Pines, Florida
H Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Emory University Hospital Midtown
Atlanta, Georgia
Emory Clinic
Atlanta, Georgia
Emory University Clinic
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Winship Cancer Institution
Atlanta, Georgia
Showing 40 of 280 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.